The Henningfield Playbook

From OxyContin to kratom: how the industry’s go‑to consultant recycled the same arguments
to protect profits and delay regulation.

Takeaways Industry Hub

⚠️ Exposed: Jack Henningfield’s testimony in 2004 for Purdue Pharma mirrors today’s kratom lobbying. Return to Industry Hub →

The Consultant Who Wrote the Script

In February 2004, Dr. Jack Henningfield testified before Congress on behalf of Purdue Pharma, the maker of OxyContin. His message: the problem was complex, deaths involved multiple substances, and aggressive restrictions would only push people to heroin. Twenty years later, Henningfield reappears — this time as a paid consultant for the American Kratom Association — using the same talking points to fight regulation.

This is not coincidence. It’s a deliberate, industry‑funded playbook designed to manufacture doubt, delay action, and keep dangerous products on the market.

The Recycled Arguments

Pattern	2004 (OxyContin)	Today (Kratom)
Polydrug deflection	“Deaths involve multiple drugs — it’s not just OxyContin.”	“Most deaths include other substances; kratom alone is rarely the cause.”
Substitution scare	“Ban OxyContin and users will turn to heroin.”	“Schedule kratom and users will turn to fentanyl.”
Call for more data	“Surveillance is incomplete — we need more research before acting.”	“Poison center data is misleading; we don’t have the full picture.”
Regulate, don’t prohibit	“Risk management, education, monitoring — not bans.”	“Industry standards, age limits, alkaloid caps — not scheduling.”

The language changes, the substance stays the same. It’s a blueprint for regulatory delay.

Why This Matters

Henningfield isn’t an independent scientist — he’s a high‑priced consultant who has worked for tobacco companies, opioid manufacturers, and now the kratom trade. His testimony is not science; it’s a litigation‑proof narrative designed to protect corporate interests.

When industry repeats “the science isn’t settled,” they don’t want more research — they want no regulation. They exploit uncertainty to keep selling unapproved, untested drugs in gas stations and vape shops.

⛔ Takeaway Points

The playbook is borrowed: Henningfield’s kratom testimony mirrors his 2004 OxyContin defense — word for word, tactic for tactic.
Polydrug is a smokescreen: Blaming “other substances” ignores that kratom itself is a psychoactive drug sold without oversight.
“Regulation not bans” is a stall: Industry‑backed “consumer protection” bills create an illusion of safety while preserving market access.
Uncertainty ≠ safety: Repeating “we need more data” is a delay tactic, not a public health position.

Read the Full Investigation

For a detailed breakdown of Henningfield’s testimony, including transcripts and side‑by‑side comparisons, see the complete analysis from Mothers Against Herbal Abuse.

READ THE FULL ANALYSIS →